Safety and efficacy of Adct-402 (loncastuximab tesirine), a novel antibody drug conjugate, in relapsed/refractory follicular lymphoma and mantle cell lymphoma: interim results from the phase 1 first-in-human study
Authors
Caimi, PKahl, S
Hamadani, M
Carlo-Stella, C
He, S
Ungar, D
Feingold, J
Ardeshna, M
Radford, John A
Solh, M
Heffner, L
O'Connor, A
Affiliation
Epizyme, Cambridge, MAIssue Date
2018
Metadata
Show full item recordCitation
Caimi P, Kahl B, Hamadani M, Carlo-Stella C, He S, Ungar D, et al. Safety and efficacy of Adct-402 (loncastuximab tesirine), a novel antibody drug conjugate, in relapsed/refractory follicular lymphoma and mantle cell lymphoma: interim results from the phase 1 first-in-human study. Blood. 2018;132.Journal
BloodDOI
10.1182/blood-2018-99-118133Additional Links
https://dx.doi.org/10.1182/blood-2018-99-118133Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2018-99-118133